Welcome to our dedicated page for Viracta Therapeutics news (Ticker: VIRX), a resource for investors and traders seeking the latest updates and insights on Viracta Therapeutics stock.
Viracta Therapeutics, Inc. (VIRX) has issued a series of news releases that trace its evolution from an active clinical-stage precision oncology company to an organization in wind down. Company announcements describe a focus on virus-associated cancers, particularly Epstein-Barr virus (EBV)-positive lymphomas and solid tumors, and provide detailed updates on its lead product candidate, Nana-val, an all-oral combination of nanatinostat and valganciclovir.
News items have covered multiple aspects of Viracta’s development programs, including clinical data from the Phase 2 NAVAL-1 trial in relapsed or refractory EBV-positive lymphomas and from a Phase 1b/2 study in EBV-positive nasopharyngeal carcinoma and other advanced EBV-positive solid tumors. The company has reported positive antitumor activity and a generally well-tolerated safety profile for Nana-val in certain EBV-positive peripheral T-cell lymphoma (PTCL) populations, as well as productive regulatory interactions with the U.S. Food and Drug Administration regarding potential paths to registration.
Corporate and strategic developments are also documented in Viracta’s news flow. Releases describe resource reprioritizations, reductions in force, and a resizing of the board of directors as the company sought to conserve cash and focus on its EBV-positive lymphoma program. Later communications announce the closure of the pivotal NAVAL-1 trial while the board explores strategic alternatives, and ultimately, the termination of employees and a decision to wind down operations, with continued exploration of options for the development programs.
On Stock Titan’s VIRX news page, readers can review this sequence of clinical, regulatory, and corporate updates directly from Viracta’s public disclosures. This provides historical context on Nana-val’s development, Viracta’s precision oncology strategy in EBV-associated cancers, and the subsequent decisions to close trials, explore strategic alternatives, and wind down operations.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.